Product nameAnti-CBL (phospho Y700) antibody
See all CBL primary antibodies
DescriptionRabbit polyclonal to CBL (phospho Y700)
Tested applicationsSuitable for: WB, IHC-P, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
- HeLa cells; HT29 cell extracts, treated with UV; Human breast carcinoma tissue.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol, 0.88% Sodium chloride
Note: PBS is without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab131345 was purified by using epitope specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
Our Abpromise guarantee covers the use of ab131345 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 100 kDa). Incubate membrane with diluted antibody in 5% nonfat milk, 1X TBS and 0.1% Tween 20, at 4C, with gentle shaking, overnight.|
|IHC-P||1/50 - 1/100.|
|ICC/IF||1/100 - 1/200.|
FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
PathwayProtein modification; protein ubiquitination.
Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain.
DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
modificationsPhosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
- Information by UniProt
- 4732447J05Rik antibody
- C CBL antibody
- Cas Br M (murine) ecotropic retroviral transforming sequence antibody
All lanes : Anti-CBL (phospho Y700) antibody (ab131345) at 1/500 dilution
Lane 1 : HT29 cell extracts
Lane 2 : HT29 cell extracts treated with UV
Predicted band size: 100 kDa
Immunofluorescent analysis of methanol-fixed HeLa cells labelling CBL with ab131345 at 1/100 dilution.
Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling CBL with ab131345 at 1/50 dilution, in the absence (left) and presence (right) of the blocking peptide.
ab131345 has not yet been referenced specifically in any publications.